All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @thenutritionnarc on TikTok · 80s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @thenutritionnarc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I was epic has officially stopped being the magic pill and is now fretting a bone.
  2. 0:04So this is one of those cases where the headline does not tell the full story but don't worry,
  3. 0:08that's what I'm here for. These articles are claiming that Ozempic is causing a 30%
  4. 0:13increase in osteoporosis and if you don't know what that is it's basically your bones degrading
  5. 0:17and weakening over time. Osteoporosis is extremely common in people who stop working out,
  6. 0:21they end up losing all of their muscle mass and in turn they lose their bone density. And despite
  7. 0:26what a lot of people think those that are overweight actually have a decent amount of muscle mass
  8. 0:30and that is because they are doing a sort of form of resistance training all throughout the day,
  9. 0:34they physically have to carry more weight so you know their legs are stronger, their glutes,
  10. 0:38their quads and even part of their upper body. So if you lose all of this weight with Ozempic
  11. 0:42and you're not supplementing it with weight lifting your body no longer has that resistance so your
  12. 0:46muscles they go on vacation your bones they kind of degrade and that is the real reason
  13. 0:50why the risk of osteoporosis goes up it's not the Ozempic itself it's from the rapid weight loss.
  14. 0:55Putting all of the blame on the drug is completely unfair in my opinion and I still think it's a
  15. 0:59net positive because we know the effects of being overweight it is one of the number one killers in
  16. 1:04America. So if you're an Ozempic or you thought about it in our word now because you've seen all
  17. 1:07these scary headlines don't be if you start taking it just make sure you keep up with your
  18. 1:11weightlifting and resistance training and also make sure you hit your protein goal if you combine
  19. 1:15these two things you should be perfectly fine and you shouldn't have an increased risk of osteoporosis.

@thenutritionnarc's bone loss claims about Ozempic, fact-checked

Blake | NARC

TikTok creator

926.3K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide can reduce bone mineral density through multiple pathways, including reduced mechanical load from weight loss, potential changes in bone turnover markers via GLP-1 receptor activity in bone cells, and reductions in lean mass if resistance exercise is not maintained. The clinical risk is not uniform across patients and is likely amplified in postmenopausal women, older adults, and those who are sedentary during treatment. Baseline DEXA scanning and individualized guidance on protein intake and resistance training are standard considerations for long-term GLP-1 users in supervised care.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @thenutritionnarc's bone loss claims about Ozempic, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@thenutritionnarc's bone loss claims about Ozempic, fact-checked" from Blake | NARC. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide can reduce bone mineral density through multiple pathways, including reduced mechanical load from weight loss, potential changes in bone turnover markers via GLP-1 receptor activity in bone cells, and reductions in lean mass if resistance exercise is not maintained.

The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic is no longer the magic pill and has started shreddi." In this clip, the useful excerpt is: "I was epic has officially stopped being the magic pill and is now fretting a bone." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GLP-1 receptors are expressed in osteoblasts and osteoclasts, meaning semaglutide may have direct bone effects beyond weight loss.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide can reduce bone mineral density through multiple pathways, including reduced mechanical load from weight loss, potential changes in bone turnover markers via GLP-1 receptor activity in bone cells, and reductions in lean mass if resistance exercise is not maintained.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide can reduce bone mineral density through multiple pathways, including reduced mechanical load from weight loss, potential changes in bone turnover markers via GLP-1 receptor activity in bone cells, and reductions in lean mass if resistance exercise is not maintained. The clinical risk is not uniform across patients and is likely amplified in postmenopausal women, older adults, and those who are sedentary during treatment. Baseline DEXA scanning and individualized guidance on protein intake and resistance training are standard considerations for long-term GLP-1 users in supervised care.
  • Weight loss from any cause, including bariatric surgery, is associated with reduced bone mineral density. This pattern predates GLP-1 drugs and is not unique to semaglutide.
  • GLP-1 receptors are expressed in osteoblasts and osteoclasts, meaning semaglutide may have direct bone effects beyond weight loss. Zheng et al. (2022, Frontiers in Endocrinology) demonstrated measurable bone turnover changes in animal models independent of weight.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Weight loss from any cause, including bariatric surgery, is associated with reduced bone mineral density. This pattern predates GLP-1 drugs and is not unique to semaglutide.
  • GLP-1 receptors are expressed in osteoblasts and osteoclasts, meaning semaglutide may have direct bone effects beyond weight loss. Zheng et al. (2022, Frontiers in Endocrinology) demonstrated measurable bone turnover changes in animal models independent of weight.
  • Resistance training during GLP-1 treatment helps preserve lean mass and supports bone density, but does not fully eliminate bone loss risk, particularly in older adults and postmenopausal women.
  • The 30% osteoporosis risk figure circulating in headlines likely comes from observational data that does not adequately control for physical activity, baseline bone health, or comorbidities, making it easy to misattribute causation.
  • Clinical guidelines recommend protein intake of 1.2 to 1.6 grams per kilogram of body weight per day to preserve lean mass during caloric restriction, a target many people on GLP-1 medications do not meet.
  • A baseline DEXA scan before or during long-term GLP-1 therapy is a reasonable clinical consideration, especially for patients with additional bone loss risk factors. This is a conversation for a prescriber, not a TikTok comment section.
  • The creator's core argument, that blaming the drug alone misses the lifestyle component, has legitimate scientific support. But concluding that the drug has no direct bone effect goes further than current evidence allows.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @thenutritionnarc actually say?

The creator pushed back on headlines claiming Ozempic causes a "30% increase in osteoporosis," arguing the drug itself isn't the problem. Their core position: people who are overweight carry more muscle mass because they're effectively doing resistance training all day, and when they lose weight rapidly without lifting, muscles atrophy and bones follow. "It's not the Ozempic itself, it's from the rapid weight loss." They closed with practical advice to keep lifting and hit protein targets.

That's actually a more nuanced read than most TikTok health content, and the basic mechanism they're describing is real. But they smoothed over some important details, including the fact that GLP-1 drugs may have direct effects on bone metabolism that go beyond what weight loss alone explains.

Does the science back this up?

Partly, yes. The link between weight loss and bone density loss is well established, and the creator's framing of load-bearing body weight as a form of passive resistance training has physiological merit. But calling semaglutide's bone effects purely a weight-loss side effect oversimplifies what the research is showing.

A 2023 study by Pouwels et al. published in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonists were associated with a modestly increased fracture risk in real-world cohorts, though confounding from underlying disease and mobility changes made causation hard to pin down. Separately, a 2024 analysis by Gortan Cappellari et al. in the Journal of Endocrinological Investigation noted that semaglutide's effects on bone turnover markers suggest there may be receptor-level interactions beyond simple caloric deficit. The 30% figure the creator references likely comes from observational data that doesn't adequately control for baseline activity levels, making it easy to misread as a drug effect when it may partly reflect lifestyle changes post-treatment.

What did they get wrong (or right)?

They got the core mechanism mostly right. Rapid weight loss, regardless of method, is a known driver of bone mineral density reduction. Studies on bariatric surgery patients, who lose weight far faster than most Ozempic users, show similar bone loss patterns. That parallel is legitimate and the creator deserves credit for making it.

Where they went wrong is the confidence of the conclusion. Saying "it's not the Ozempic itself" is a stronger claim than the current evidence supports. GLP-1 receptors are expressed in osteoblasts and osteoclasts, the cells that build and break down bone. A 2022 paper by Zheng et al. in Frontiers in Endocrinology showed semaglutide had measurable effects on bone turnover markers independent of weight change in animal models. That doesn't prove harm in humans, but it does mean writing off the drug's direct role entirely is premature.

Their advice to lift weights and eat adequate protein is sound. But framing those two behaviors as a guarantee that users "shouldn't have an increased risk" overpromises. Resistance training reduces the risk, it doesn't eliminate it, and some users, particularly postmenopausal women, face compounding bone density risks that need clinical monitoring, not just gym time.

What should you actually know?

If you're on a GLP-1 medication and concerned about bones, the conversation belongs in a clinical setting, not a comment section. Your provider can order a DEXA scan to establish a baseline bone mineral density before or during treatment. Resistance training and adequate protein intake, generally 1.2 to 1.6 grams per kilogram of body weight per day according to current sports nutrition guidelines, are evidence-backed ways to preserve lean mass during weight loss. These are not optional extras.

The "30% increase in osteoporosis" headline the creator was reacting to almost certainly came from observational data with real limitations. That doesn't mean bone health is a non-issue on these medications. It means the picture is more complex than a single scary stat, and also more complex than "just keep lifting." Bone density monitoring, calcium and vitamin D status, and activity level all matter. Anyone on a GLP-1 drug long-term should be having that conversation with their prescriber, not getting reassurance from a TikTok video, including this one.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Blake | NARC · TikTok creator

926.3K views on this video

“Ozempic is no longer the magic pill and has started shredding bones”#greenscreen

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about weight loss from any cause, including bariatric surgery,?

Weight loss from any cause, including bariatric surgery, is associated with reduced bone mineral density. This pattern predates GLP-1 drugs and is not unique to semaglutide.

What does the video say about glp-1 receptors?

GLP-1 receptors are expressed in osteoblasts and osteoclasts, meaning semaglutide may have direct bone effects beyond weight loss. Zheng et al. (2022, Frontiers in Endocrinology) demonstrated measurable bone turnover changes in animal models independent of weight.

What does the video say about resistance training during glp-1 treatment helps preserve lean mass?

Resistance training during GLP-1 treatment helps preserve lean mass and supports bone density, but does not fully eliminate bone loss risk, particularly in older adults and postmenopausal women.

What does the video say about the 30% osteoporosis risk figure circulating in headlines likely comes?

The 30% osteoporosis risk figure circulating in headlines likely comes from observational data that does not adequately control for physical activity, baseline bone health, or comorbidities, making it easy to misattribute causation.

What does the video say about clinical guidelines recommend protein intake of 1.2 to 1.6 grams?

Clinical guidelines recommend protein intake of 1.2 to 1.6 grams per kilogram of body weight per day to preserve lean mass during caloric restriction, a target many people on GLP-1 medications do not meet.

What does the video say about a baseline dexa scan before?

A baseline DEXA scan before or during long-term GLP-1 therapy is a reasonable clinical consideration, especially for patients with additional bone loss risk factors. This is a conversation for a prescriber, not a TikTok comment section.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Blake | NARC, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.